Niklaus G Schaefer

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT
    Niklaus G Schaefer
    Department of Internal Medicine, Clinic for Medical Oncology, University Hospital Zurich, Switzerland
    Eur J Radiol 81:e19-25. 2012
  2. ncbi Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
    Niklaus G Schaefer
    Division of Nuclear Medicine, Department of Radiology, University Hospital Zurich, Zurich, Switzerland
    Radiology 244:257-62. 2007
  3. ncbi Bone involvement in patients with lymphoma: the role of FDG-PET/CT
    Niklaus G Schaefer
    Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland
    Eur J Nucl Med Mol Imaging 34:60-7. 2007
  4. ncbi Potential use of humanized antibodies in the treatment of breast cancer
    Niklaus G Schaefer
    Medical Oncology, Department of Internal Medicine, University Hospital Zurich, Raemistr, 100, CH 8091 Zurich, Switzerland
    Expert Rev Anticancer Ther 6:1065-74. 2006
  5. ncbi Feasibility of integrated CT-liver perfusion in routine FDG-PET/CT
    Patrick Veit-Haibach
    Department of Medical Radiology, Division of Nuclear Medicine, University Hospital Zuerich, Raemistrasse 100, 8091, Zuerich, Switzerland
    Abdom Imaging 35:528-36. 2010
  6. ncbi Changing PET/CT manifestation of neurolymphomatosis
    Klaus Strobel
    Division of Nuclear Medicine, University Hospital Zurich, , 8091 Zurich, Switzerland
    Eur J Nucl Med Mol Imaging 33:1244. 2006
  7. ncbi Influence of bowel preparation before 18F-FDG PET/CT on physiologic 18F-FDG activity in the intestine
    Jan D Soyka
    Department of Nuclear Medicine, University Hospital, Zurich, Switzerland
    J Nucl Med 51:507-10. 2010
  8. ncbi Pulmonary hypertrophic osteoarthropathy in a patient with nonsmall cell lung cancer: Diagnosis with FDG PET/CT
    Klaus Strobel
    Division of Nuclear Medicine, Department of Medical Radiology, University Hospital Zurich, Zurich, Switzerland
    Clin Nucl Med 31:624-6. 2006
  9. ncbi Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component
    Patrick Veit-Haibach
    Department of Medical Radiology, Division of Nuclear Medicine, University Hospital Zurich, Zuerich, Switzerland
    Eur Radiol 21:256-64. 2011
  10. ncbi Combined PET/CT-perfusion in patients with head and neck cancers
    Patrick Veit-Haibach
    Department of Radiology, Division of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland
    Eur Radiol 23:163-73. 2013

Detail Information

Publications15

  1. ncbi Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT
    Niklaus G Schaefer
    Department of Internal Medicine, Clinic for Medical Oncology, University Hospital Zurich, Switzerland
    Eur J Radiol 81:e19-25. 2012
    ..To prospectively analyze different FDG-PET/CT-parameters (modified RECIST, SUVmax, TLG, PETvol) in patients with malignant pleural mesothelioma (MPM) under continued pemetrexed and platin based treatment...
  2. ncbi Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
    Niklaus G Schaefer
    Division of Nuclear Medicine, Department of Radiology, University Hospital Zurich, Zurich, Switzerland
    Radiology 244:257-62. 2007
    ....
  3. ncbi Bone involvement in patients with lymphoma: the role of FDG-PET/CT
    Niklaus G Schaefer
    Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland
    Eur J Nucl Med Mol Imaging 34:60-7. 2007
    ..To evaluate the diagnostic impact and clinical significance of FDG-avid bone lesions detected by FDG-PET/CT in patients with lymphoma...
  4. ncbi Potential use of humanized antibodies in the treatment of breast cancer
    Niklaus G Schaefer
    Medical Oncology, Department of Internal Medicine, University Hospital Zurich, Raemistr, 100, CH 8091 Zurich, Switzerland
    Expert Rev Anticancer Ther 6:1065-74. 2006
    ..Here, an overview of humanized antibodies in human breast cancer is provided, with emphasis on the recent advances and future prospects in treating malignant breast cancer...
  5. ncbi Feasibility of integrated CT-liver perfusion in routine FDG-PET/CT
    Patrick Veit-Haibach
    Department of Medical Radiology, Division of Nuclear Medicine, University Hospital Zuerich, Raemistrasse 100, 8091, Zuerich, Switzerland
    Abdom Imaging 35:528-36. 2010
    ..To integrate CT-perfusion into a routine, clinical contrast-enhanced (ce) PET/CT protocol for the evaluation of liver metastases and to compare functional CT and PET parameters...
  6. ncbi Changing PET/CT manifestation of neurolymphomatosis
    Klaus Strobel
    Division of Nuclear Medicine, University Hospital Zurich, , 8091 Zurich, Switzerland
    Eur J Nucl Med Mol Imaging 33:1244. 2006
  7. ncbi Influence of bowel preparation before 18F-FDG PET/CT on physiologic 18F-FDG activity in the intestine
    Jan D Soyka
    Department of Nuclear Medicine, University Hospital, Zurich, Switzerland
    J Nucl Med 51:507-10. 2010
    ..Our objective was to investigate the use of bowel preparation before (18)F-FDG PET/CT to reduce intestinal (18)F-FDG uptake...
  8. ncbi Pulmonary hypertrophic osteoarthropathy in a patient with nonsmall cell lung cancer: Diagnosis with FDG PET/CT
    Klaus Strobel
    Division of Nuclear Medicine, Department of Medical Radiology, University Hospital Zurich, Zurich, Switzerland
    Clin Nucl Med 31:624-6. 2006
  9. ncbi Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component
    Patrick Veit-Haibach
    Department of Medical Radiology, Division of Nuclear Medicine, University Hospital Zurich, Zuerich, Switzerland
    Eur Radiol 21:256-64. 2011
    ..To assess the clinical value of multi-phase, contrast-enhanced DOPA-PET/CT with emphasis on the diagnostic CT component in patients with neuroendocrine tumours (NET)...
  10. ncbi Combined PET/CT-perfusion in patients with head and neck cancers
    Patrick Veit-Haibach
    Department of Radiology, Division of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland
    Eur Radiol 23:163-73. 2013
    ..The aim of the study was to investigate the relationship between FDG and CTP data in patients with head and neck cancers...
  11. ncbi Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysis
    Axel Mischo
    University Hospital Zurich, Department of Oncology, Ramistr 100, CH 8091 Zurich, Switzerland
    Int J Oncol 39:287-94. 2011
    ..We rarely found IgG2 and IgG4 subclass antibodies. Our results support the implication that target-specific antibodies raised after vaccination contribute to the stimulation of an effective T cell response against the target antigen...
  12. ncbi Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?
    Niklaus G Schaefer
    Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, CH 8091 Zurich, Switzerland
    Radiology 232:823-9. 2004
    ....
  13. ncbi Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer
    Jan D Soyka
    Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland
    Eur J Nucl Med Mol Imaging 39:936-43. 2012
    ..To investigate the clinical value of (18)F-fluorocholine PET/CT (CH-PET/CT) in treatment decisions in patients with recurrent prostate cancer (rPCA)...
  14. ncbi Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP
    Panagiotis Samaras
    Department of Oncology, University Hospital Zurich, Switzerland
    Ann Hematol 89:783-7. 2010
    ..068). Concomitant statin use had no adverse impact on response to chemotherapy, EFS, and OS in patients treated with R-CHOP for DLBCL...
  15. ncbi Incidence and intensity of F-18 FDG uptake after vaccination with H1N1 vaccine
    Irene A Burger
    Division of Nuclear Medicine, Department Medical Radiology, University Hospital of Zurich, Zurich, Switzerland
    Clin Nucl Med 36:848-53. 2011
    ..To analyze the effect of H1N1 influenza A virus vaccination in patients referred for staging or follow-up F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for different malignant tumors...